BIL010t
Basal Cell Carcinoma (Topical)
Pre-clinicalAvailable for Out-licensing
Key Facts
Indication
Basal Cell Carcinoma (Topical)
Phase
Pre-clinical
Status
Available for Out-licensing
Company
About Biosceptre
Biosceptre is pioneering a multi-targeted universal CAR T-cell therapy platform, BRiDGECAR™, centered on the novel oncology target nfP2X7. With Nobel prize-winning scientific leadership and foundational research from the University of Sydney, the company is advancing a pipeline intended to address numerous malignancies. Recently securing £8.1 million in funding, Biosceptre is positioned to accelerate its innovative programs, though it remains a preclinical-stage, pre-revenue entity facing significant development and competitive risks.
View full company profile